Spots Global Cancer Trial Database for metastatic pancreatic ductal adenocarcinoma
Every month we try and update this database with for metastatic pancreatic ductal adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04990037 | Metastatic Panc... | CAN04 FOLFIRINOX | 18 Years - | Cantargia AB | |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | NCT06390059 | Metastatic Panc... | Tumor Treating ... Atezolizumab Gemcitabine nab-paclitaxel | 18 Years - | NovoCure Ltd. | |
| Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | NCT02583477 | Metastatic Panc... | MEDI4736 in com... MEDI4736 in com... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | NCT05558982 | Metastatic Panc... | BXCL701 Pembrolizumab | 18 Years - | Georgetown University | |
| Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | NCT02558894 | Metastatic Panc... | MEDI4736 monoth... tremelimumab+ME... | 18 Years - | AstraZeneca | |
| A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients | NCT04581343 | Metastatic Panc... | Canakinumab inj... | 18 Years - | Pancreatic Cancer Action Network | |
| A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) | NCT05472259 | Metastatic Panc... | Nanoliposomal i... 5 FU Leucovorin Oxaliplatin | 18 Years - | Belgian Group of Digestive Oncology | |
| Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer | NCT04631445 | Metastatic Panc... | Ketogenic Diet | 18 Years - | Translational Drug Development | |
| FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | NCT06206876 | Advanced Pancre... Locally Advance... Metastatic Panc... Refractory Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Biopsy Biospecimen Col... Computed Tomogr... DDX5 Degrader F... Magnetic Resona... | 18 Years - | Roswell Park Cancer Institute | |
| A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | NCT05630183 | Metastatic Panc... | Botensilimab Gemcitabine Nab-paclitaxel | 18 Years - | Agenus Inc. | |
| Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | NCT04493060 | Metastatic Panc... Stage IV Pancre... | Dostarlimab Niraparib | 18 Years - | Mayo Clinic | |
| A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy | NCT03331640 | Metastatic Panc... | OFF FOLFIRI Protoco... | 18 Years - | AIO-Studien-gGmbH | |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | NCT06398587 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Onvansertib Gemcitabine Nab-paclitaxel Electrocardiogr... Magnetic Resona... Positron Emissi... Biospecimen Col... Biospecimen Col... Computed Tomogr... | 18 Years - | OHSU Knight Cancer Institute | |
| Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | NCT04821284 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Gemcitabine Hyd... Nab-paclitaxel Fluorouracil Irinotecan Hydr... Leucovorin Calc... Oxaliplatin Perflubutane Mi... Contrast-Enhanc... Quality-of-Life... Computed Tomogr... Magnetic Resona... | 18 Years - | Thomas Jefferson University | |
| Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | NCT05642962 | Metastatic Panc... Metastatic Panc... Metastatic Panc... Metastatic Panc... Pancreatic Carc... Pancreatic Carc... Pancreatic Carc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... PDAC PDAC - Pancreat... | Pertzye | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | NCT04809766 | Metastatic Panc... Stage IV Pancre... | Autologous Meso... Cyclophosphamid... Fludarabine Bendamustine | 18 Years - | Fred Hutchinson Cancer Center | |
| A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | NCT05630183 | Metastatic Panc... | Botensilimab Gemcitabine Nab-paclitaxel | 18 Years - | Agenus Inc. | |
| A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy | NCT03331640 | Metastatic Panc... | OFF FOLFIRI Protoco... | 18 Years - | AIO-Studien-gGmbH | |
| A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | NCT06168812 | Pancreatic Canc... Pancreatic Carc... Pancreatic Duct... Pancreatic Canc... Metastatic Panc... Metastatic Panc... | Glipizide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | NCT02600949 | Metastatic Colo... Metastatic Panc... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Imiquimod Pembrolizumab Sotigalimab Synthetic Tumor... Computed Tomogr... Magnetic Resona... | 18 Years - | M.D. Anderson Cancer Center | |
| PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 | NCT05737615 | Pancreatic Canc... Pancreatic Duct... Metastatic Panc... Primary Pancrea... Metastatic Panc... | PET Scan hu5B1-TCO 64Cu-Tz-SarAr Pharmacokinetic... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | NCT04821284 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Gemcitabine Hyd... Nab-paclitaxel Fluorouracil Irinotecan Hydr... Leucovorin Calc... Oxaliplatin Perflubutane Mi... Contrast-Enhanc... Quality-of-Life... Computed Tomogr... Magnetic Resona... | 18 Years - | Thomas Jefferson University | |
| Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients | NCT04888312 | Metastatic Panc... | CD40 agonist mi... | 18 Years - | Alligator Bioscience AB | |
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | NCT04666740 | Metastatic Panc... Homologous Reco... | Pembrolizumab Olaparib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC | NCT02501902 | Metastatic Panc... | Palbociclib Nab-Paclitaxel | 18 Years - | Pfizer | |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | NCT05685602 | Metastatic Panc... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Biopsy Biospecimen Col... Computed Tomogr... Emavusertib Gemcitabine Hyd... Magnetic Resona... Nab-paclitaxel Positron Emissi... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | NCT04612530 | Pancreatic Canc... Metastatic Panc... | Irreversible El... Nivolumab Toll-Like Recep... | 18 Years - 100 Years | Amsterdam UMC, location VUmc | |
| Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT02101021 | Metastatic Panc... | Momelotinib Placebo to matc... Nab-paclitaxel Gemcitabine | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer | NCT04005690 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Cobimetinib Olaparib Onvansertib Azenosertib | 18 Years - | OHSU Knight Cancer Institute | |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | NCT02600949 | Metastatic Colo... Metastatic Panc... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Imiquimod Pembrolizumab Sotigalimab Synthetic Tumor... Computed Tomogr... Magnetic Resona... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04329949 | Metastatic Panc... | Relacorilant, 1... Nab-paclitaxel | 18 Years - | Corcept Therapeutics | |
| A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) | NCT05472259 | Metastatic Panc... | Nanoliposomal i... 5 FU Leucovorin Oxaliplatin | 18 Years - | Belgian Group of Digestive Oncology | |
| Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | NCT04935359 | Metastatic Panc... | NIS793 Nab-paclitaxel Gemcitabine Placebo | 18 Years - | Novartis | |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | NCT06398587 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Onvansertib Gemcitabine Nab-paclitaxel Electrocardiogr... Magnetic Resona... Positron Emissi... Biospecimen Col... Biospecimen Col... Computed Tomogr... | 18 Years - | OHSU Knight Cancer Institute | |
| A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients | NCT04581343 | Metastatic Panc... | Canakinumab inj... | 18 Years - | Pancreatic Cancer Action Network | |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04329949 | Metastatic Panc... | Relacorilant, 1... Nab-paclitaxel | 18 Years - | Corcept Therapeutics | |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer | NCT04005690 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Cobimetinib Olaparib Onvansertib Azenosertib | 18 Years - | OHSU Knight Cancer Institute | |
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma | NCT04292743 | Locally Advance... Metastatic Panc... | Eryaspase FOLFIRINOX | 18 Years - | Georgetown University | |
| Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | NCT04809766 | Metastatic Panc... Stage IV Pancre... | Autologous Meso... Cyclophosphamid... Fludarabine Bendamustine | 18 Years - | Fred Hutchinson Cancer Center | |
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma | NCT04292743 | Locally Advance... Metastatic Panc... | Eryaspase FOLFIRINOX | 18 Years - | Georgetown University | |
| A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX | NCT03450018 | Metastatic Panc... | SLC-0111 Gemcitabine Inj... | 18 Years - | British Columbia Cancer Agency |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
